

## **AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application.**

1. **(Original)** A method of increasing expression of GLUT4 in a subject comprising administering to the subject a GDF-8 inhibitor.
2. **(Original)** A method of increasing insulin sensitivity and glucose uptake by cells in a subject comprising administering to the subject a GDF-8 inhibitor.
3. **(Original)** A method of treating diabetes in a subject comprising administering to the subject a GDF-8 inhibitor.
4. **(Cancelled)**
5. **(Original)** The method of any one of claims 1-3, wherein the GDF-8 inhibitor is selected from the group consisting of a peptide fragment of GDF-8, a dominant-negative mutant of GDF-8, a GDF-8 receptor antagonist, a non-GDF-8 peptide, an antisense nucleic acid and a ribozyme.
6. **(Original)** The method of any one of claims 1-3, wherein the GDF-8 inhibitor is derived from mature GDF-8 protein.
7. **(Original)** The method of any one of claims 1-3, wherein the GDF-8 inhibitor is derived from the Pro domain of a GDF-8 protein.
8. **(Original)** The method of claim 2, wherein said insulin sensitivity and glucose uptake is increased by modulating the expression of a hexose transporter selected from the group consisting of GLUT4 and GLUT1

9. **(Cancelled)**

10. **(Cancelled)**

11. **(Original)** The method of claim 3, wherein the subject is suffering from type II diabetes.